Delivery Order SPE2DB24D2205-SPE2DB25FECUA

Award Date 5/22/25
Potential Completion Date 5/23/25
Potential Value $24K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,180.20, is for the delivery of IPOL VIAL 5ML, a pharmaceutical product. The contract has a firm fixed price and is scheduled for completion by May 8, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $12,645.16, is for the delivery of IPOL VIAL 5ML pharmaceutical products. It is a firm fixed-price contract with a period of performance through May 1, 2025. The contract is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $42,694.00, is for the procurement of IPOL VIAL 5ML medical products. This is a firm fixed-price delivery order that does not have a set-aside designation, indicating open competition. The contract has an ultimate completion date of May 29, 2024. Amerisourcebergen holds a significant Indefinite...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $21,347.00 firm fixed-price contract is for the delivery of IPOL VIAL 5ML medical supplies, with a period of performance through April 18, 2024. The award is not designated as a set-aside contract. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
This federal contract award is a delivery order from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $21,802.00, is for the delivery of IPOL VIAL 5ML, a pharmaceutical product. The contract is a firm fixed-price delivery order with a period of performance through May 7, 2025. The contract is not set-aside and represents open competition. Amerisourcebergen Drug Corp is the prime...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $21,802.00, is for the delivery of IPOL VIAL 5ML medical products. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC provides a comprehensive...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,668.52 firm fixed-price delivery order is for the supply of 4567951715 IPOL VIAL 5ML, with a performance period ending on April 18, 2025. The contract is not set aside and is considered an open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the...
This federal contract award is a delivery order worth $20,920.06 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, awarded by the Defense Logistics Agency (DLA). The contract is for the delivery of IPOL VIAL 5ML medical supplies with a performance period through September 30, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,270.30, is for the delivery of IPOL VIAL 5ML pharmaceutical products. It is a firm fixed price, non-set-aside contract with a performance period ending on May 12, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of IPOL VIAL 5ML medical products. The contract has a ceiling value of $102,390.83 and an ultimate completion date of September 23, 2024. It is a firm fixed-price contract, with no set-aside designation. Amerisourcebergen, through its extensive supply chain network, will provide a wide range of pharmaceutical...
  • SPE2DB24D2205
    Indefinite Delivery Contract
  • SPE2DB24D2205-SPE2DB25FECUA
    Delivery Order

This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $24,308.80 firm-fixed-price contract is for the delivery of IPOL VIAL 5ML pharmaceutical products. The contract has an ultimate completion date of May 23, 2025.

Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as SPE2DX, which provides a comprehensive global pharmaceutical support vehicle with a performance period extending through December 2026. This IDC enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard. The current delivery order is not designated as a set-aside contract.

Generated 8/21/25, 9:47 AM